Chronic daily headache prophylaxis with tizanidine: A double-blind, placebo-controlled, multicenter outcome study

Headache

Volumn 42, Issue 6, 2002, Pages 470-482

  Saper, Joel R ^a   Lake III, Alvin E ^a   Cantrell, Deborah T ^b   Winner, Paul K ^c   White, Jeffery R ^d  

^a Michigan Head Pain/Neurol Institute   (United States)

^b Baylor Medical Center   (United States)

^c Palm Beach Headache Center   (United States)

^d ELAN PHARMACEUTICALS   (United States)

Author keywords

Chronic daily headache; Chronic migraine; Chronic tension type headache; Double blind study; Placebo controlled; Prophylaxis; Tizanidine

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; PLACEBO; TIZANIDINE; CLONIDINE; DRUG DERIVATIVE;

ADULT; ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; ASTHENIA; BREAST CANCER; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOMNOLENCE; SUICIDAL BEHAVIOR; TENSION HEADACHE; TREATMENT OUTCOME; VAGINA BLEEDING; VERTIGO; VISUAL ANALOG SCALE; XEROSTOMIA; ADOLESCENT; CHRONIC DISEASE; CLASSIFICATION; HEADACHE AND FACIAL PAIN; MIDDLE AGED;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ADULT; CHRONIC DISEASE; CLONIDINE; DOUBLE-BLIND METHOD; FEMALE; HEADACHE DISORDERS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0036617410     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2002.02122.x     Document Type: Article

References (42)

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
2. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998;38:497-506.
3. Castillo J, Muñoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache. 1999;39:190-196.
4. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology. 2000;54:314-319.
5. Mathew NT. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin. 1997;15:167-186.
6. Rothrock J, Patel M, Lyden P, Jackson C. Demographic and clinical characteristics of patients with episodic migraine versus chronic daily headache. Cephalalgia. 1996;16:44-49.
7. Saper JR, Lake AE III, Madden SF, Kreeger C. Comprehensive/tertiary care for headache: a 6-month outcome study. Headache. 1999;39:249-263.
8. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache. 1987;27:102-106.
9. Spierings EL, Ranke AH, Schroevers M, Honkoop PC. Chronic daily headache: a time perspective. Headache. 2000;40:306-310.
10. Nappi G, Granella F, Sandrini G, Manzoni GC. Chronic daily headache. How should it be included in the IHS classification? Headache. 1999;39:197-203.
11. Monzon MJ, Lainez MJ. Quality of life in migraine and chronic daily headache patients. Cephalalgia. 1998;18:638-643.
12. Redillas C, Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache. 2000;40:83-102.
13. Ramadan N, Silberstein SD, Freitag FG, Gilbert T, Frishberg B. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. Neurology [serial online]. Available at: http://www.neurology. org. Accessed April 25, 2000.
14. Mathew NT. Medication misuse headache. Cephalalgia. 1998;18(suppl 21):34-36.
15. Srikiatkhachorn A, Tarasub N, Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache. 2000;40:343-350.
16. Grazzi L, Andrasik F, D'Amico D, et al. Behavioural approach in the treatment of chronic daily headache with drug overuse: a 3-year follow-up study [abstract]. Cephalalgia. 2000;20:300.
17. Holroyd KA, O'Donnell FJ, Stensland M, Lipchik GL, Cordingley G, Carlson B. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. JAMA. 2001;285:2208-2215.
18. Lake AE III. Behavioral and nonpharmacologic treatments of headache. Med Clin North Am. 2001;85:1055-1075.
19. Nance PW. Alpha-adrenergic and serotinergic agents in the treatment of spastic hypertonia. Phys Med Rehab Clin North Am. 2001;12:889-904.
20. Kameyama T, Nabeshima T, Sugimoto A, Matsuno K, Yamada S. Antinociceptive action of tizanidine in mice and rats. Naunyn Schmiedebergs Arch Pharmacol. 1985;330:93-96.
21. Nabeshima T, Matsuno K, Kameyama T. Involvement of spinal and supraspinal structures in tizandine-induced antinociceptive action. Neurosci Lett. 1986;63:1-4.
22. 2-adrenoreceptors. Neuropharmacology. 1987;26:1453-1455.
23. Berry H, Hutchinson DR. Tizanidine and ibuprofen in acute low-back pain: results of a double-blind multicentre study in general practice. J Int Med Res. 1988;16:83-91.
24. Berry H, Hutchinson DR. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. J Int Med Res. 1988;16:75-82.
25. Zanaflex [package insert]. South San Francisco, Calif: Elan Pharmaceuticals; 2000.
26. Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study. Headache. 1992;32:509-513.
27. Murros K, Kataja M, Hedman C, et al. Modified-release formulation of tizanidine in chronic tension-type headache. Headache. 2000;40:633-637.
28. Shimomura T, Awaki E, Kowa H, Takahashi K. Treatment of tension-type headache with tizanidine hydrochloride: its efficacy and relationship to the plasma MHPG concentration. Headache. 1991;31:601-604.
29. Krusz JC, Belanger J, Mills C. Tizanidine: a novel effective agent for treatment of chronic headaches. Headache Q. 2000;11:41-45.
30. Saper JR, Winner P, Lake AE III. An open-label dose-titration study of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache. Headache. 2001;41:357-368.
31. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88:41-52.
32. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
33. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology. 2000;54:1553.
34. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20:765-786.
35. Bendtsen L, Jensen R, Olesen J. A non-selective (amytriptyline) but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996;61:285-290.
36. Pfaffenrath V, Diener HC, Isler H, et al., Efficacy and tolerability of amytriptylinoxide in the treatment of chronic tension-type headache: a multi-centre controlled study. Cephalalgia. 1994;14:149-155.
37. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack. Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123(pt 8):1703-1709.
38. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001;89:107-110.
39. Fusco BM, Colantoni O, Giacovazzo M. Alteration of central excitation circuits in chronic headache and analgesic misuse. Headache. 1997;37:486-491.
40. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;1:658-660.
41. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41:629-637.
42. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache. 1987;27:416-420.